87 results about "Thrombopoietin" patented technology

Methods of treating mitochondrial respiratory chain disorders using compounds having erythropoietin activity or thrombopoietin activity are disclosed. Indicators for assessing the efficacy of treatment are discussed.

The present invention provides a method for expanding an endothelial progenitor cell in vitro. More particularly, the present invention provides a method for culturing a hemangioblast comprising incubating a hemangioblast in a serum-free culture medium containing one or more factors selected from the group consisting of stem cell growth factor, interleukin-6, FMS-like tyrosine kinase 3 and thrombopoietin, and a vascular endothelial cell produced by the method; and a serum-free culture medium containing one or more factors selected from the group consisting of stem cell growth factor, interleukin-6, FMS-like tyrosine kinase 3 and thrombopoietin, and a kit for the preparation of the serum-free culture medium and the like.

The present inventors used antibody engineering techniques to prepare functional antibodies that correspond to individual mutations in causative genes of diseases, and discovered that such antibodies enable the treatment of the diseases. Specifically, the inventors succeeded in preparing ligands, particularly minibodies, which have agonistic activity to receptors that have almost completely lost responsiveness to their natural ligands because of gene mutations (for example, a thrombopoietin (TPO) receptor whose reactivity to TPO has been markedly impaired), and which can transduce signals by interacting with these mutant receptors at levels comparable to normal.

Disclosed herein are novel diazenyl pyrazole compounds and related compounds. Also disclosed herein are methods of using these compounds for the treatment of diseases and conditions associated with modulating a thrombopoietin activity.

Provided is a megakaryocyte and/or platelet production method, enabling to produce a megakaryocyte and/or platelet from mesenchymal cells such as preadipocytes in a relatively short period of time, simply, in a large amount and at lower cost or more efficiently in vitro and a method for producing TPO simply and in a larger amount. A first invention is a method for producing a megakaryocyte and/or platelet, comprising culturing a mesenchymal cell in a mesenchymal cell culturing basic medium containing an iron ion and an iron transporter and collecting megakaryocytes and/or platelets from a culture. A second invention is a method for producing thrombopoietin, comprising culturing a mesenchymal cell or mesenchymal cell-derived megakaryocyte in a mesenchymal cell culturing basic medium containing an iron ion and an iron transporter and collecting thrombopoietin from a culture. A third invention is a method for producing thrombopoietin, comprising culturing a preadipocyte in a preadipocyte culturing basic medium containing dexamethasone, 3-isobutyl-1-methylxanthine and insulin and collecting thrombopoietin from a culture.

The present invention provides methods for the identification of CD4⁺ T-cell epitopes in the sequences of various proteins, namely, human cytokines and cytokine receptors, as well as the production of peptides which when incorporated into the protein sequence, are no longer capable of initiating the CD4⁺ T-cell response. In some embodiments, the present invention provides means and compositions suitable for reducing the immunogenicity of cytokines and cytokines receptors such as interferon-β, soluble tumor necrosis factor receptor-1, erythropoietin, and thrombopoietin.

The invention relates to a stem cell amplifying culture medium and a stem cell culture method. The ingredients of the stem cell amplifying culture medium comprise a basic culture medium, a stem cell factor, thrombopoietin, an FMS like tyrosine kinase 3 ligand and interleukin-6, wherein the final concentration of the stem cell factor is 90ng/mL-110ng/mL, the final concentration of the thrombopoietin is 10ng/mL-30ng/mL, the final concentration of the FMS like tyrosine kinase 3 ligand is 90ng/mL-110ng/mL, and the final concentration of the interleukin-6 is 10ng/mL-30ng/mL. When the stem cell amplifying culture medium is used for culturing cord blood hematopoietic stem cells, obvious cell amplifying effects can be presented, CD34+ on cell surfaces is also notably increased, during cell amplification, the cell state is stable, the multi-directional differentiation capacity is maintained, and the culture medium is an economic efficient culture system.

The invention provides a culture medium of umbilical cord mesenchymal stem cells. The culture medium comprises a DMEM (Dulbecco's Modified Eagle Medium)/F12 culture medium, an adding component added into the DMEM/F12 culture medium and ivy extract, wherein the adding component is prepared from the following components: human serum albumin, transferrin, a vascular endothelial growth factor, a basicfibroblast growth factor, arginine, a leukemia inhibitory factor, a stem cell factor, beta cytokine, parathyroid hormone, a platelet-derived growth factor, a tumor necrosis factor alpha, interleukin,erythropoietin, thrombopoietin, alpha-D-glucose, vitamin C, resveratrol, NaHCO3 and ganglioside; the ivy extract is liquid and is extracted from leaves of ivy through a conventional method; the finalconcentration is 20 to 50mg/L after the ivy extract is added. By adopting the culture medium, the problems in the prior art are solved, and the cells can keep good state and proliferation speed.

The present invention provides a method for expanding and improving functional capacity of human adult-derived progenitor cells in vitro using a closed culture system. The present invention provides a favorable condition for cell therapy to promote tissue repair and organogenesis via vasculogenesis and angiogenesis in clinical settings. The proposed closed bag culture system for culturing hemangioblast comprises of, in one embodiment, a serum-free culture medium containing one or more factors selected from the group consisting of stem cell growth factor, interleukin-6, FMS-like tyrosine kinase 3, thrombopoietin, and vascular endothelial growth factor and a kit for the preparation of the serum-free culture medium and the like.

A method for recognizing and evaluating the presence and function of GnRH receptors on tumor cells originating in the brain and/or nervous system and/or the meninges and/or reactive neuroglia cells and/or primitive neuroectodermal tumor cells and/or on Kaposi sarcoma is provided. Furthermore a method for reducing degenerate GnRH-positive tumor cells and/or for decreasing cellular replication of the above GnRH-positive tumor cells comprising administering to a cell or to a subject a replication decreasing amount of a GnRH agonist and/or GnRH antagonist and/or an erythropoietin agonist, and/or a thrombopoietin agonist, and/or a endothelin antagonist and/or a gonadotropin inhibiting hormone agonist is also provided. Furthermore, a diagnostic kit for detecting GnRH receptors on tumor cells according to the present methods is disclosed.

The invention relates to a stem cell in-vitro multiplication method. A multiplication culture system containing niacinamide substances is adopted, a serum-free culture medium is used as a basic culture medium, and 8%-12% of fetal bovine serum, a cytokine composition and niacinamide substances are added. The cytokine composition includes a stem cell factor, thrombopoietin, an FLt3 ligand, G-CSF, IL-3 and IL-6. Compared with conventional culture systems, the culture system can effectively increase the number of hematopoietic stem cells and the cell proportion of CD34+/Lin- and CD34+/CD38- when culturing CD34+ cells for 1-12 weeks and is helpful to solving of the problem of insufficient cells in hematopoietic stem cell transplantation.

The invention provides a construction method and application of a thrombopoietin (THPO) gene humanized non-human animal. The method comprises the following steps: introducing a sequence for encoding human THPO protein into an animal genome by using a homologous recombination manner; the animal can normally express the human or humanized THPO protein in vivo, to promote the development of human T cells and NK cells; the non-human animal can be used as an animal model for human THPO signal mechanism research and drug screening for diseases including tumors and the like, and has important application value for new drug research and development of immune targets. The invention further provides a targeting vector of a THPO gene, sgRNA of the target THPO gene and application of the targeting vector and the sgRNA to preparation of a humanized THPO gene.

The invention relates to the field of compounds, especially peptides or polypeptides, that have thrombopoietic activity. The peptides and polypeptides of the invention may be used to increase platelets of platelet precursors (e.g., megakaryocytes) in a mammal.

The present disclosure relates to a method for preparing recombinant glycoproteins with high sialic acid content. More specifically, for UDP-GlcNAc 2-epimerase/ManNAc kinase (GNE/MNK) enzyme where point mutation was induced by substituting arginine at position 263 by leucine only or by further substituting arginine at position 266 by glutamine, epimerase activity is constantly maintained, and overexpressed cells thereof experience an increase in intracellular cytidine monophosphate (CMP)-sialic acid content, irrespective of CMP-sialic acid concentration.,Particularly, since in an glycoprotein(such as, erythropoietin and thrombopoietin)-producing host cell where point mutationinduced GNE/MNK, human alpha-2,3-sialyltransferase and a CMP-sialic acid transporter gene are simultaneously overexpressed, intracellular content of CMP-sialic acid and sialic acid in glycoprotein increases in cells, overexpression in a host cell producing a sialylated recombinant glycoprotein the three genes above may be useful for preparing glycoprotein with increased sialic acid content.

The invention provides a fusion protein produced through restructuring targeted thrombopoietin (TPO), which comprises a TPO simulated peptide region and a human growth hormone polypeptide region, bridge joint peptides are arranged between the two regions. The invention also provides the preparing method and use of the fusion protein.

The invention belongs to the technical field of biological medicines and particularly relates to a biological marker group for optic neuromyelitis spectrum diseases, application of the biological marker group, a protein chip and a kit. The invention provides an optic neuromyelitis spectrum disease biomarker group which is characterized by comprising monocyte chemotactic protein-3, LIGHT, macrophage inflammatory protein-1 delta, insulin-like growth factor-2, a glucocorticoid induced tumor necrosis factor receptor, thrombopoietin and a herpes virus entry medium, wherein the LIGHT is a lymphotoxin analogue which can be induced and expressed on a T cell and competes with glycoprotein D of HSV to be combined with HVEM. The application fills the blank that no reliable and accurate product and method for diagnosing and identifying optic neuromyelitis lineage diseases exist clinically at present.

The present invention includes a method for excluding patients from the need for further analysis of Alzheimer's Disease comprising: obtaining a blood or serum sample from a patient in a primary care setting; determining the expression levels of at least 4 of the following proteins: FABP, beta 2 microglobulin, PPY, soluble tumor necrosis factor receptor 1 (sTNFR1), CRP, VCAM-1, thrombopoietin, α2 macroglobulin, eotaxin 3, tumor necrosis factor-alpha (TNF-α), tenascin C (TNC), IL-5, IL-6, IL-7, IL-10, IL-18, 1309, Factor VII, thymus and activation-regulated chemokine (TARC), serum amyloid A (SAA), and intercellular cell-adhesion molecule-1 (ICAM-1); comparing the level of expression from the sample with a statistically locked-down, multi-ethnic, broad age spectrum statistical sample; and determining if the patient is excluded from further testing for Alzheimer's Disease, thereby eliminating the need for further testing of the patient.

In various embodiments methods of producing a cell population enriched for CLEC9A+ dendritic cells are provided where the methods involve culturing stem cells and/or progenitor cells in a cell culture comprising culture medium, a notch ligand, stem cell factor (SCF), FLT3 ligand (FLT3L); thrombopoietin (TPO); and IL-3 and/or GMCSF.